These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 17539845

  • 1. Clinical characteristics of tuberculosis in patients with liver cirrhosis.
    Cho YJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.
    Respirology; 2007 May; 12(3):401-5. PubMed ID: 17539845
    [Abstract] [Full Text] [Related]

  • 2. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 3. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE.
    Arch Intern Med; 2006 Sep 25; 166(17):1863-70. PubMed ID: 17000943
    [Abstract] [Full Text] [Related]

  • 4. Pneumoconiosis and liver cirrhosis are not risk factors for tuberculosis in patients with pulmonary infection.
    Wu HP, Pan YH, Hua CC, Shieh WB, Jiang BY, Yu TJ.
    Respirology; 2007 May 25; 12(3):416-9. PubMed ID: 17539848
    [Abstract] [Full Text] [Related]

  • 5. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb 25; 30(2):179-83. PubMed ID: 19565883
    [Abstract] [Full Text] [Related]

  • 6. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE.
    Expert Opin Drug Saf; 2004 May 25; 3(3):187-98. PubMed ID: 15155147
    [Abstract] [Full Text] [Related]

  • 7. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM, Ruslami R, Suroto AJ, Burger DM, Alisjahbana B, van Crevel R, Aarnoutse RE.
    Clin Infect Dis; 2007 Oct 15; 45(8):1001-7. PubMed ID: 17879915
    [Abstract] [Full Text] [Related]

  • 8. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, Li YP.
    Int J Tuberc Lung Dis; 2006 Oct 15; 10(10):1080-90. PubMed ID: 17044199
    [Abstract] [Full Text] [Related]

  • 9. [The tolerability and therapeutic efficacy of rifabutin in the treatment of pulmonary tuberculosis].
    Parola D, Dell'Orso D, Giovagnoli S, Bianconi S, Terzano C.
    Recenti Prog Med; 1999 May 15; 90(5):254-7. PubMed ID: 10380552
    [Abstract] [Full Text] [Related]

  • 10. Outcome and management of spinal tuberculosis according to the severity of disease: a retrospective study of 137 adult patients at Korean teaching hospitals.
    Park DW, Sohn JW, Kim EH, Cho DI, Lee JH, Kim KT, Ha KY, Jeon CH, Shim DM, Lee JS, Lee JB, Chun BC, Kim MJ.
    Spine (Phila Pa 1976); 2007 Feb 15; 32(4):E130-5. PubMed ID: 17304122
    [Abstract] [Full Text] [Related]

  • 11. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
    Pitche P, Mouzou T, Padonou C, Tchangai-Walla K.
    Med Trop (Mars); 2005 Sep 15; 65(4):359-62. PubMed ID: 16548490
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
    Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN.
    Clin Infect Dis; 2007 Sep 15; 45(6):715-22. PubMed ID: 17712755
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for rifampin-monoresistant tuberculosis: A case-control study.
    Sandman L, Schluger NW, Davidow AL, Bonk S.
    Am J Respir Crit Care Med; 1999 Feb 15; 159(2):468-72. PubMed ID: 9927359
    [Abstract] [Full Text] [Related]

  • 14. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection.
    Haley CA, Stephan S, Vossel LF, Sherfy EA, Laserson KF, Kainer MA.
    Int J Tuberc Lung Dis; 2008 Feb 15; 12(2):160-7. PubMed ID: 18230248
    [Abstract] [Full Text] [Related]

  • 15. [Clinical features of 23 cases of AIDS complicated by tuberculosis].
    Yuan J, Yu WY, Hu YW, Jiang XL, Luo ZY, Wen B, Liu Y, Wu M.
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Nov 15; 27(11):767-70. PubMed ID: 15634391
    [Abstract] [Full Text] [Related]

  • 16. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003.
    Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR.
    Arch Intern Med; 2008 Oct 13; 168(18):1984-92. PubMed ID: 18852399
    [Abstract] [Full Text] [Related]

  • 17. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
    Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, García JF, Martínez JA, Caylà JA, Tuberculosis Prevention Working Group.
    Int J Tuberc Lung Dis; 2005 Mar 13; 9(3):276-81. PubMed ID: 15786890
    [Abstract] [Full Text] [Related]

  • 18. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA.
    Int J Infect Dis; 2009 Sep 13; 13(5):e236-40. PubMed ID: 19285897
    [Abstract] [Full Text] [Related]

  • 19. [Tuberculosis complicated with liver cirrhosis].
    Saito A, Nagayama N, Yagi O, Ohshima N, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2006 Jul 13; 81(7):457-65. PubMed ID: 16910597
    [Abstract] [Full Text] [Related]

  • 20. Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi.
    Beadsworth MB, van Oosterhout JJ, Diver MJ, Faragher EB, Shenkin A, Mwandumba HC, Khoo S, O'Dempsey T, Squire SB, Zijlstra EE.
    Int J Tuberc Lung Dis; 2008 Mar 13; 12(3):314-8. PubMed ID: 18284838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.